Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Bridgewater Associates LP

Bridgewater Associates LP increased its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 55.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,678 shares of the medical equipment provider's stock after acquiring an additional 39,216 shares during the quarter. Bridgewater Associates LP owned about 0.16% of Lantheus worth $9,812,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Lantheus by 47.7% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock valued at $1,041,000 after buying an additional 3,772 shares during the period. Empirical Asset Management LLC purchased a new position in Lantheus during the fourth quarter worth approximately $323,000. Focus Financial Network Inc. acquired a new stake in Lantheus in the fourth quarter valued at approximately $292,000. Harbor Capital Advisors Inc. raised its stake in shares of Lantheus by 12.8% during the 4th quarter. Harbor Capital Advisors Inc. now owns 145,379 shares of the medical equipment provider's stock worth $13,006,000 after buying an additional 16,466 shares during the period. Finally, World Investment Advisors LLC acquired a new stake in Lantheus in the 3rd quarter valued at $60,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on LNTH. Truist Financial lifted their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. JMP Securities reissued a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, B. Riley cut their price objective on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Insider Activity at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 63,109 shares of company stock valued at $6,016,046 over the last three months. 2.00% of the stock is owned by corporate insiders.

Lantheus Stock Up 1.0 %

NASDAQ:LNTH traded up $1.05 during trading hours on Tuesday, reaching $101.67. 81,933 shares of the stock were exchanged, compared to its average volume of 949,806. The business has a 50-day moving average of $95.76 and a two-hundred day moving average of $95.33. Lantheus Holdings, Inc. has a twelve month low of $62.59 and a twelve month high of $126.89. The company has a market capitalization of $6.96 billion, a price-to-earnings ratio of 16.92 and a beta of 0.20.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.